Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
详细信息 查看全文
- 作者：Marí ; a-Belé ; n Vidrialesa ; b ; Estefaní ; a Pé ; rez-Ló ; peza ; estefipe83@hotmail.com" class="auth_mail" title="E-mail the corresponding author ; Carlota Pegenautea ; Marta Castellanosa ; José ; -Juan Pé ; reza ; Mauricio Chandí ; aa ; Joaquí ; n Dí ; az-Mediavillac ; Consuelo Rayó ; nd ; Natalia de las Herase ; Pascual Ferná ; ndez-Abellá ; nf ; Miguel Cabezudog ; Alfonso Garcí ; a de Cocah ; Jose Mª ; Alonsoi ; Carmen Olivierj ; Jesú ; s Mª ; Herná ; ndez-Rivasa ; b ; Pau Montesinosk ; Rosa Ferná ; ndezl ; Julio Garcí ; a- Suá ; rezm ; Magdalena Garcí ; an ; Marí ; a-José ; Sayaso ; Bruno Paivaa ; b ; Marcos Gonzá ; leza ; b ; Alberto Orfaob ; p ; Jesú ; s F. San Miguela ; b ; For PETHEMA Programa para el Estudio de la Terapé ; utica en Hemopatí ; as Malignas Cooperative Study Group
- 关键词：Flow cytometry ; Minimal residual disease ; Acute myeloid leukaemia ; Prognosis
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：40
- 期：Complete
- 页码：1-9
- 全文大小：1326 K
文摘
- •
Prognostic impact of MRD after induction therapy by flow cytometry in 306 AML patients.
- •
Allogeneic transplantation is better than autologous in patients with MRD > 0.1%.
- •
MRD has special interest in the intermediate cytogenetic group.
- •
Scoring system based on MRD and cytogenetics for the prognostic stratification.